DalCor is a biopharmaceutical company focused on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver dalcetrapib, the first pharmacogenomic precision medicine in cardiovascular disease that specifically targets patients with the ADCY9 AA genotype.
Dalcetrapib is currently being evaluated in the dal-GenE Phase 3 cardiovascular clinical outcomes trial aiming to reduce major adverse cardiovascular events (MACE). dal-GenE passed a futility analysis in January 2020 and trial completion is expected in the first half of 2021. To date, dalcetrapib has been administered, with a good safety and tolerability profile, for more than two years to over 10,000 patients with cardiovascular diseases and risk factors such as obesity, diabetes, and hypertension.
dal-GenE has enrolled 6,149 patients with post-acute coronary syndrome (ACS) who have the AA genotype at rs1967309 location in the ADCY9 gene. About 20% of the total population has this specific genotype. In a retrospective analysis of a previous trial these patients were identified to have a potentially improved cardiovascular outcome when treated with dalcetrapib.
A companion diagnostic test, developed in conjunction with Roche Molecular Systems, identifies patients with the ADCY9 AA genotype who may potentially benefit from dalcetrapib treatment. DalCor obtained global rights to develop, manufacture and commercialize dalcetrapib under a license and collaboration agreement with Roche.
DalCor has exclusive world-wide rights to develop and commercialize dalcetrapib and CETP inhibitors for the treatment of cardiovascular diseases in patients who have one or more improved response genotypes through at least 2034.